Non-profit R&D group DNDi points up progress fighting neglected diseases
Geneva-based non-profit the Drugs for Neglected Diseases initiative (DNDi) has released its annual report for 2016, detailing plans to register fexinidazole as a new drug to treat sleeping sickness.
The drug R&D institute says that if regulatory approval is granted next year, as it expects, the drug would become its first new chemical entity to reach this milestone. The group entered into a collaboration with Sanofi (Euronext: SAN) to develop fexinidazole in 2009.
The DNDi, which conducts its own clinical development programs drawing from a mix of public and private donations, has a pipeline of over 30 projects targeting some of the world’s most neglected diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze